Based on this study, we suggest that ENO2 acts as an oncogenic driver in HNSCC development and targeting it using the ENO inhibitor AP-III-a4 represents a potential therapeutic approach for treating this type of cancer. This evidence concerns the gene ENO2 and head and neck squamous cell carcinoma.